<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657433</url>
  </required_header>
  <id_info>
    <org_study_id>1807765944</org_study_id>
    <nct_id>NCT03657433</nct_id>
  </id_info>
  <brief_title>Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy</brief_title>
  <official_title>Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial includes pregnant women with anemia. They are randomized to
      IV iron infusions or to oral iron supplementation. Pregnancy outcomes are assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial aimed at assessing whether IV Iron administration
      (Ferumoxytol x 2 infusions) is superior to oral ferrous sulfate for the treatment of
      iron-deficiency anemia in pregnancy.

      140 patients will be randomized in a 1:1 ratio. Patients in the IV Iron group will receive
      two infusions of Ferumoxytol, one week apart. Patients in the oral Ferrous Sulfate group will
      receive medication to take at home during their pregnancy.

      Patients will have iron studies performed at study entry, and again at presentation for
      delivery. Cord blood will also be sampled for iron studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>We will assess the increase in maternal hemoglobin during the study timeframe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in other laboratory values</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Including hematocrit, serum iron, transferrin saturation, ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss at delivery</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Estimated or quantified blood loss at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin change after delivery</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Measured change in hemoglobin after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Whether the mother requires a blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron infusion</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Whether the mother requires additional iron infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of substances in cord blood (iron studies)</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Cord blood indices for iron, transferrin saturation and ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Whether the delivery occurs at less than 37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for delivery</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Indication for delivery if not spontaneous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>1 day - 22 weeks</time_frame>
    <description>Neonatal weight immediately after delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Iron Deficiency Anemia of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Ferumoxyltol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.
Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.
Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous sulfate 325mg</intervention_name>
    <description>Oral tablets supplied for home use</description>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>Ferumoxytol will be administered in two infusions, one week apart</description>
    <arm_group_label>Ferumoxyltol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age &gt;/= 18

          -  Singleton gestation

          -  &gt;/=20 weeks gestation, &lt;37 weeks gestation

          -  Hemoglobin &lt;11g/dL and/or hematocrit &lt;33%

          -  Able to read/speak English or Spanish

        Exclusion Criteria:

          -  Maternal age &lt;18

          -  Multiple gestation

          -  &lt;20 weeks gestation, &lt;/= 37 weeks gestation

          -  Hemoglobin &gt;/=11g/dL and/or hematocrit &gt;/=33%

          -  Unable to read or speak English or Spanish

          -  Incarcerated patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meghan G Hill, MBBS</last_name>
    <phone>502 626 6174</phone>
    <email>meghanhill@obgyn.arizona.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adeola Awomolo, MD</last_name>
    <phone>520 626 6174</phone>
    <email>awomoloa@obgyn.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan G Hill, MBBS</last_name>
      <phone>520-626-6174</phone>
      <email>meghanhill@obgyn.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adeola Awomolo, MD</last_name>
      <phone>520 626 6174</phone>
      <email>awomoloa@obgyn.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Meghan G Hill, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeola Awomolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Meghan Hill</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

